Using transgenic mouse models of pediatric intractable epilepsy and brain overgrowth to define new therapeutics and mechanisms
Overgrowth diseases are rooted in the dysregulation of genetic pathways that control tissue growth and maturity. Depending on the location of dysregulation, overgrowth syndromes can express as disproportionate growth of extremities or tumor formation. However when seen in the brain, there can be severe neurological pathologies including autism, impaired cognition, and epilepsy. One of the more common overgrowth disorders, megalencephaly, is estimated to be expressed in 2% of children and is often associated with autistic characteristics. Treatment currently involves managing symptoms, leaving the underlying disease process unaddressed.
Dr. Kathleen Millen
One branch of Dr. Millen’s research focuses on genetic brain overgrowth diseases that have varying pathological expression depending on when the genetic pathways are activated. Mutations in the catalytic subunit of phosphoinositide 3-kinase (PIK3CA) and other PI3K-AKT pathway components have been associated with cancer seen in adults, and a wide spectrum of brain and body overgrowth are usually caused by gene dysfunction starting in utero. In the brain, the phenotypic spectrum of PIK3CA-related segmental overgrowth includes bilateral dysplastic megalencephaly, hemimegalencephaly, and focal cortical dysplasia, the most common cause of intractable pediatric epilepsy.
Dr. Millen’s group generated mouse models expressing the most common activating PIK3CA mutations (H1047R and E545K) in developing neural progenitors. These accurately recapitulate all the key human pathological features including brain enlargement, cortical malformation, hydrocephalus and epilepsy, with phenotypic severity dependent on the mutant allele and its time of activation. Underlying mechanisms include increased proliferation, cell size, and altered white matter.
Additional disease areas of interest to Dr. Millen include human cerebellar malformations such as Dandy-Walker malformation, cerebellar vermis hypoplasia, and rhombencephalosynapsis. These disorders are caused by disruptions of brain development during early embryogenesis and are often accompanied by other birth defects, including hydrocephalus and agenesis of the corpus callosum. Understanding the genetic dysfunctions that cause these malformations is critically important in helping manage symptoms and developing long-term treatment options.
Dr. Millen is interested in using her animal models in pursuit of testing new treatments for brain overgrowth and cerebellar malformations, with an emphasis on understanding the link between these diseases and epilepsy. Additionally, her lab group maintains a robust mouse development program that could be used to produce disease models using transgenic techniques.
Stage of Development
- Pre-clinical in vitro
- Pre-clinical in vivo
- Collaborative research opportunity
- Development opportunity
- Sponsored research agreement
- Consultation agreement
- Collaborative animal model development
- Roy A, Skibo J, Kalume F, Ni J, Rankin S, Lu Y, Dobyns W, Mills G, Zhao J, Baker S, Millen K. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. eLife. 2015;4.
- Roy A, Ni J, Skibo J, Rankin S, Dobyns W, Kalume F, Baker S, Zhao J, Millen K. Modeling human PIK3CA-related congenital brain overgrowth and epilepsy in mice. International Journal of Developmental Neuroscience. 2015;47:46.
- Aldinger K, Lehmann O, Hudgins L, Chizikov V, Bassuk A, Ades L,Krantz I, Dobyns W, Millen K. FOXC1 is required for normal cerebellar development and is a major contributor to chromosome 6p25.3 Dandy-Walker malformation. Nature Genetics. 2009;41(9):1037-1042.
To learn more about partnering with Seattle Children’s Research Institute on this or other projects, please contact:
Dr. Elizabeth Aylward
Director, Office of Science-Industry Partnerships